Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases Academic Article uri icon

Overview

MeSH Major

  • Bone Neoplasms
  • Prostatic Neoplasms
  • Receptors, Platelet-Derived Growth Factor

abstract

  • These clinical and translational results question the value of PDGFR inhibition with taxane chemotherapy in prostate cancer bone metastases and are at variance with the preclinical studies. This discordance requires explanation.

publication date

  • October 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-07-1269

PubMed ID

  • 17908974

Additional Document Info

start page

  • 5816

end page

  • 24

volume

  • 13

number

  • 19